http://hdl.handle.net/11434/8 Fri, 17 Apr 2026 18:06:55 GMT 2026-04-17T18:06:55Z http://hdl.handle.net/11434/2419 Title: An evaluation of elranatamab for the treatment of myeloma: current evidence for treating relapsed/refractory disease and future directions. Epworth Authors: Bayly-McCredie, Elena; Prince, Miles; Yannakoua, Costas; Fiorenza, Salvatore; Wisniowskia, Brendan Abstract: The development of B-cell maturation antigen (BCMA)-directed therapies has been a significant advancement for the treatment of multiple myeloma. Elranatamab is a bispecific antibody (BsAb) targeting BCMA and CD3. It has achieved regulatory approval in several jurisdictions worldwide for the treatment of patients with relapsed/refractory multiple myeloma. Clinical trials of elranatamab in various settings are currently ongoing. This article describes the current evidence for treating relapsed/refractory multiple myeloma with elranatamab. A search for relevant literature was conducted in PubMed, EMBASE, Cochrane Library, and hematology conference abstracts published between 2017 and 2025. Citation mining of the included studies was also conducted. Elranatamab monotherapy has demonstrated manageable safety and encouraging efficacy in relapsed/refractory multiple myeloma. The overall toxicity profile is comparable to other BCMA-targeting BsAbs. The low grade of cytokine release syndrome (CRS) supports the administration of elranatamab in the outpatient setting. High infection rates remain a challenge, although further refinement of anti-infection prophylaxis and adjustment of the dosing schedule may reduce the risk. Clinical trials are currently investigating elranatamab in different settings to further enhance the efficacy, including as a first-line treatment and combination regimens, although benefits need to be weighed against the increased toxicity risk. Sun, 01 Mar 2026 00:00:00 GMT http://hdl.handle.net/11434/2419 2026-03-01T00:00:00Z http://hdl.handle.net/11434/2401 Title: Efficacy and cost-effectiveness of an online mindfulness program (MindOnLine) to reduce fear of recurrence among people with cancer: study protocol for a randomised controlled trial Epworth Authors: Wootten, Addie; Gillan, Kate Abstract: Introduction: Fear of cancer recurrence (FCR) is a common condition among cancer survivors that can lead to significant levels of distress, anxiety and depression. Online mindfulness programmes may provide the mechanism to support cancer survivors manage FCR and distress, and improve people’s well-being over the short, medium and long term. The primary aim of this study is to determine the potential efficacy of MindOnLine, a 9 session mindfulness-based programme for survivors of breast, prostate and colorectal cancer. A formal economic programme will also be conducted. Methods and analysis: A single-blind randomised controlled trial to determine the efficacy and cost-efficacy of a MindOnLine programme for cancer survivors. A total of 400 people living with cancer will be recruited via online advertisements on social media platforms, peak consumer advocacy groups or through outpatient services at healthcare providers across Victoria, Australia. People will be randomly allocated to either the MindOnLine programme (n=200) or waitlist control (n=200). Participant assessments will occur at baseline, at 9 weeks and 9-month follow-up. The primary outcome is change in Fear of Recurrence Index Score total score between baseline and 9 weeks; secondary outcomes are changes in depression and anxiety, quality of life and mindfulness. The economic analysis comprises a cost-consequences analysis where all outcomes will be compared with costs. Ethics and dissemination: Ethics approval was obtained from the Peter MacCallum Cancer Centre (20-53) and Deakin University (2020-284). All participants will be required to provide written informed consent. Findings will be disseminated in peer reviewed journals and among key stakeholder organisations including hospitals, cancer and community organisations and Government. If successful the project will be rolled out nationally with a formal implementation plan. Sat, 01 Jan 2022 00:00:00 GMT http://hdl.handle.net/11434/2401 2022-01-01T00:00:00Z http://hdl.handle.net/11434/2341 Title: Improving outcomes in pancreatic cancer surgery: benchmarking existing data for pancreatic surgery outcomes, stakeholder-lead development of the Pancreatic Cancer Surgical Outcome (PaCaSO) registry, and exploration of pancreatic cancer resection rate in Victoria. Epworth Authors: Lockie, Elizabeth; Zalcberg, John Abstract: Surgery with chemotherapy offers the best chance of long-term survival in pancreatic cancer. This suite of studies centres around optimising surgery for pancreatic cancer and the development of a bi-national registry. Fri, 01 Aug 2025 00:00:00 GMT http://hdl.handle.net/11434/2341 2025-08-01T00:00:00Z http://hdl.handle.net/11434/2332 Title: Primary retroperitoneal lymph node dissection in stage II testicular seminoma: a systematic review. Epworth Authors: Liu, Jianliang; Woon, Dixon; Lawrentschuk, Nathan Abstract: Objective: To conduct a systematic review of the current literature to determine the current role of primary retroperitoneal lymph node dissection (RPLND) in stage II testicular seminoma and its associated oncological, functional and peri-operative outcomes. Materials and methods: A comprehensive literature search was conducted in Medline, Embase, and Scopus for publications from inception until November 2023. The systematic review was registered on PROSPERO (ID CRD42023449781), was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and utilised the Methodological Index for Non-Randomised Studies (MINORS) tool. Results: Six studies involving 385 patients were analysed, with 48.5% clinical stage IIA and 51.5% stage IIB seminomas. The patients' mean (range) age was 37 (20-64) years. The median operation time was 187 min, median estimated blood loss was 150 mL and median length of hospital stay was 4 days. In all, 6.1% of patients developed complications that were greater or equal to Clavien-Dindo grade 3. Only four studies reported on anejaculation rate (median: 4.9%). Only one study had long-term data, demonstrating a 92% 5-year overall survival for stage IIA/B disease treated with RPLND. The remaining five studies had a median follow-up of between 18.5 and 37 months and reported a mean recurrence rate of 15.6%. Most recurrences (78%) were not within the field of RPLND. Recurrence was associated with higher clinical and pathological lymph node stage, and metachronous or delayed development of retroperitoneal lymphadenopathy (initially stage I disease, as opposed to de novo stage IIA/B disease). Discussion: Primary RPLND, performed by experienced surgeons, has good peri-operative outcomes. Recurrence is more common than with standard treatment, but long-term survival and functional data are limited, although promising. Sat, 01 Feb 2025 00:00:00 GMT http://hdl.handle.net/11434/2332 2025-02-01T00:00:00Z